New research explores how an acute dose of MitoQ impacts claudication onset, maximal walking time, and leg artery dilation in patients with Peripheral Artery Disease.

A randomised, double-blind crossover trial assessing whether 6 weeks of Mitoquinol supplementation (20 mg/day) improves endothelial function, reduces aortic stiffness, and attenuates mitochondrial oxidative stress in healthy adults aged 60–79. 

A double‑blind trial examining whether 3 weeks of Mitoquinol supplementation during high‑intensity interval training (HIIT) enhances mitochondrial and vascular adaptation without blunting exercise‑induced redox signalling.

A controlled study assessing whether a single high dose of Mitoquinol restores flow‑mediated dilation in postmenopausal women and what this reveals about the mitochondrial basis of menopause‑related vascular ageing.